FDAnews Drug Daily Bulletin

GLAXOSMITHKLINE'S CERVICAL CANCER CANDIDATE VACCINE FORMULATED WITH THE AS04 ADJUVANT MORE EFFECTIVE

July 13, 2006
A A

Glaxosmithkline plc, a research-based pharmaceutical and healthcare company, said on Wednesday data from the first two studies published in Vaccine showed that GSK's cervical cancer candidate vaccine formulated with the AS04 adjuvant system not only evoked higher and more sustained antibody levels but also stronger immune memory response. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/303420/)